Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATNM with free AI briefings, catalyst countdowns, and dilution alerts.

ATNM · Actinium Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$36.5M Cash on Hand
19.8mo Cash Runway
Follow ATNM by email Get an email when ATNM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATNM, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Hematopoietic Stem Cell Transplant… Acute Leukemia Phase 2/3 · NCT07157514 Not yet recruiting
Iodine I 131 Apamistamab Acute Myeloid Leukemia Phase 3 · NCT02665065 Active not recruiting
Conventional Care Acute Myeloid Leukemia Phase 3 · NCT02665065 Active not recruiting
131I-apamistamab Acute Leukemia Phase 2/3 · NCT07157514 Not yet recruiting
Fludarabine Acute Leukemia Phase 2/3 · NCT07157514 Not yet recruiting
Lintuzumab-Ac225 Acute Myeloid Leukemia Phase 1/2 · NCT03867682 Unknown
Chimeric Antigen Receptor T-cells Non Hodgkin Lymphoma Phase 1/2 · NCT06768905 Recruiting
Lintuzumab AC 225 Refractory Multiple Myeloma Phase 1 · NCT02998047 Terminated
Actinium Ac 225 Lintuzumab Leukemia Phase 1 · NCT00672165 Completed
131I-apamistmab Sickling Disorder Due to Hemoglobin S Phase 1 · NCT07015684 Recruiting

Also used in these trials (approved or third-party drugs, not ATNM's own candidates): Cyclophosphamide, Cytarabine, Venetoclax, Spironolactone, Furosemide, Azacitidine, Alemtuzumab, Sirolimus.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATNM holds $36.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.5M/quarter from operations, an estimated runway of 19.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATNM files for a raise →

👥 Who Owns ATNM

Insiders 9.1% Institutions (57 holders) 16.8% Public and other holders 74.1%
HolderTypeShares% of sharesAs of
Sandesh Seth
Chief Executive Officer, Director · +1.13M options
Insider 1,965,355 6.25% 2026-09-02
Matthew T David
Chief Financial Officer · +250,000 options
Insider 250,000 0.80% 2026-10-14
Adeela Kamal
Chief Scientific Officer
Insider 213,648 0.68% 2026-09-03
Steffen Wilhem Heeger
Chief Medical Officer
Insider 153,868 0.49% 2026-09-03
C. David Nicholson,
Director · +94,200 options
Insider 63,300 0.20% 2026-09-02
Richard I Steinhart
Director · +94,200 options
Insider 63,116 0.20% 2026-09-02
Ajit Shetty
Director · +92,400 options
Insider 62,357 0.20% 2026-09-02
Jeffrey W. Chell
Director · +92,400 options
Insider 61,600 0.20% 2026-09-02
June Sherie Almenoff
Director · +27,000 options
Insider 18,000 0.06% 2026-09-02

Share count 31,441,436 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ATNM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATNM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.